| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/10/2011 | US7939515 Administration of fluocinolone acetonide, tretinoin and hydroquinone cream in melasma maintenance therapy |
| 05/10/2011 | US7939514 Administration of fluocinolone acetonide, tretinoin and hydroquinone cream in melasma maintenance therapy |
| 05/10/2011 | US7939513 Tetracycline derivatives as antibacterial agents |
| 05/10/2011 | US7939512 Multistep process for the physical depolymerization of heparin and products obtained therefrom |
| 05/10/2011 | US7939511 Ophthalmic composition containing xanthan gum and amino acid |
| 05/10/2011 | US7939510 Di(uridine 5′-)tetraphosphate and salts thereof |
| 05/10/2011 | US7939509 Partial and full agonists of A1 adenosine receptors |
| 05/10/2011 | US7939508 RNAi inhibition of alpha-ENaC expression |
| 05/10/2011 | US7939504 Method of treating skin ulcers with vectors encoding hepatocyte growth factor |
| 05/10/2011 | US7939503 Nucleotide sequences coding six transmembrane epithelial antigen of the prostate (STEAP)-1) for use as tool in diagnosis, prevention and treatment of cell proliferative disorders; RNA intereference |
| 05/10/2011 | US7939502 Optimised formulation of tobramycin for aerosolization |
| 05/10/2011 | US7939500 Antifungal paints and coatings |
| 05/10/2011 | US7939468 Methods of identifying compounds that target tRNA splicing endonuclease and uses of said compounds as anti-proliferative agents |
| 05/10/2011 | US7939292 Modified heparinase III and methods of sequencing therewith |
| 05/10/2011 | US7939268 Compositions and methods for the diagnosis and treatment of tumor |
| 05/10/2011 | US7939118 Oligosaccharide mixture |
| 05/10/2011 | US7939113 Nutritional composition for facilitating muscle pumps |
| 05/10/2011 | US7939109 Method of treating neoplastic disease in a human or animal patient |
| 05/10/2011 | US7939104 Granulation; compaction; rapid dissolution upon contact with physiological solvents such as water, saliva or gastrointestinal fluids |
| 05/10/2011 | US7939102 Controlled release formulation of lamotrigine |
| 05/10/2011 | US7939100 Tulobuterol adhesive patch |
| 05/10/2011 | US7939099 Sustained improver of muscular fatigue |
| 05/10/2011 | US7939098 Compositions and method for transmucosal drug delivery and cryoprotection |
| 05/10/2011 | US7939094 Multiphase polymeric drug release region |
| 05/10/2011 | US7939074 Combination of an anti-EP-CAM antibody with a chemotherapeutic agent |
| 05/10/2011 | US7939073 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 05/10/2011 | US7939066 Methods and compositions for the inhibition of growth of infectious Aspergillus fumigatus and other mycotic organisms in the gut of mammalian and avian species |
| 05/10/2011 | US7939060 Equol-containing composition comprising daidzein for use in prevention and treatment of bone disorders |
| 05/10/2011 | US7939055 Polymeric aromatic N-halo sulfonamides |
| 05/10/2011 | US7939054 Compositions for removing hair |
| 05/10/2011 | US7938641 Extrusion die |
| 05/10/2011 | CA2718460A1 Compositions for intratumoral administration |
| 05/10/2011 | CA2671369C Crystal of benzimidazole compound |
| 05/10/2011 | CA2622805C Compressed tablets comprising valsartan |
| 05/10/2011 | CA2621805C Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4) |
| 05/10/2011 | CA2614746C Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes |
| 05/10/2011 | CA2566436C Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| 05/10/2011 | CA2565850C Tetrahydrocarbazole derivatives with biological action and solubility as ligands for g-protein coupled receptors (gpcrs) |
| 05/10/2011 | CA2519063C Immunomodulating heterocyclic compounds |
| 05/10/2011 | CA2501322C Quinolinyl-pyrrolopyrazoles |
| 05/10/2011 | CA2494208C N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion |
| 05/10/2011 | CA2487388C Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments |
| 05/10/2011 | CA2485535C Modified release pharmaceutical formulation |
| 05/10/2011 | CA2483105C Autoimmune conditions and nadph oxidase defects |
| 05/10/2011 | CA2480033C In vivo use of glutathionone s-transferase activated nitric oxide donors |
| 05/10/2011 | CA2478335C Amino-methyl substituted tetracycline compounds |
| 05/10/2011 | CA2477172C Uses of compositions for inhibiting nf-.kappa.b mediated tumorigenicity and adhension-dependent survival of cancer cells |
| 05/10/2011 | CA2477004C Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| 05/10/2011 | CA2475498C Piperidine derivative and pharmaceutical composition comprising the same as active ingredient |
| 05/10/2011 | CA2473572C Quinazoline compounds |
| 05/10/2011 | CA2467471C Derivatives of andrimid and moiramide b having antibacterial properties |
| 05/10/2011 | CA2463102C Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors |
| 05/10/2011 | CA2460436C Stabilization of active agents by formulation into nanoparticulate form |
| 05/10/2011 | CA2454976C Therapeutic agent for glaucoma comprising compound having pi3 kinase inhibitory action as active ingredient |
| 05/10/2011 | CA2451279C Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligands of the adenosine a2a receptor and their use as medicaments |
| 05/10/2011 | CA2450359C Dosage regimen and pharmaceutical composition for emergency contraception |
| 05/10/2011 | CA2436935C Serine protease inhibitors |
| 05/10/2011 | CA2433158C Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor |
| 05/10/2011 | CA2427899C Microgranules based on active principle and method for making same |
| 05/10/2011 | CA2419633C Substituted imidazoles as tafia inhibitors |
| 05/10/2011 | CA2418815C Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative |
| 05/10/2011 | CA2417806C New immunoeffector compounds |
| 05/10/2011 | CA2411056C Pharmaceutical compositions containing prostacyclin synthase gene |
| 05/10/2011 | CA2406664C Systemic delivery of neural stem cells to treat cancer |
| 05/10/2011 | CA2382560C Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease |
| 05/10/2011 | CA2377373C Nitric oxide donors for inducing neurogenesis |
| 05/10/2011 | CA2375605C Peptide leukotriene receptor |
| 05/10/2011 | CA2292898C Bacterial pheromones and uses therefor |
| 05/10/2011 | CA2248016C Direct molecular diagnosis of friedreich ataxia |
| 05/10/2011 | CA2171589C Phosphonomonoester nucleic acids, process for their preparation, and their use |
| 05/10/2011 | CA2165458C Intracellular binding proteins and use thereof |
| 05/06/2011 | CA2741886A1 Preservative system for emulsion-based therapeutic topical formulations |
| 05/05/2011 | WO2011053948A1 Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals |
| 05/05/2011 | WO2011053938A1 Methods and compositions for treating cancer |
| 05/05/2011 | WO2011053917A2 Gastroretentive oral high dose zinc preparations |
| 05/05/2011 | WO2011053876A1 The use of ci-994 and dinaline for the treatment of memory/cognition and anxiety disorders |
| 05/05/2011 | WO2011053870A1 Alleviating oxidative stress disorders with pufa derivatives |
| 05/05/2011 | WO2011053861A1 Kinase inhibitors |
| 05/05/2011 | WO2011053848A1 Methylsulfonylmethane (msm) for treatment of drug resistant microorganisms |
| 05/05/2011 | WO2011053829A1 Dosing regimen associated with long-acting injectable paliperidone esters |
| 05/05/2011 | WO2011053812A1 Methods of treating viral associated diseases |
| 05/05/2011 | WO2011053801A2 Methods and cosmetic preparations for the sustained delivery of therapeutic agents to the eye |
| 05/05/2011 | WO2011053792A2 Methods and compositions for sustained delivery of drugs |
| 05/05/2011 | WO2011053706A1 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators |
| 05/05/2011 | WO2011053705A1 Pyrimidine compounds as delta opioid receptor modulators |
| 05/05/2011 | WO2011053701A1 Phenoxy-substituted pyrimidines as opioid receptor modulators |
| 05/05/2011 | WO2011053697A1 2-aminoindole compounds and methods for the treatment of malaria |
| 05/05/2011 | WO2011053696A1 Pyrazines as delta opioid receptor modulators |
| 05/05/2011 | WO2011053660A2 Novel therapeutic rna interference technology targeted to the pdx-1 oncogene in pdx-1 expressing neuroendocrine tumors |
| 05/05/2011 | WO2011053617A1 Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin |
| 05/05/2011 | WO2011053614A1 Crystalline cdm-nag and methods for producing same |
| 05/05/2011 | WO2011053597A1 Pipemidic acid derivative autotaxin inhibitors |
| 05/05/2011 | WO2011053575A1 Spirolactam derivatives and uses of same |
| 05/05/2011 | WO2011053574A1 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS |
| 05/05/2011 | WO2011053571A1 Phytoestrogenic formulations for alleviation or prevention of hair loss |
| 05/05/2011 | WO2011053569A1 Ophthalmic formulation and method of manufacture thereof |
| 05/05/2011 | WO2011053567A1 Hexahydrocyclopentyl[f]indazole pyridyl ethanols and derivatives thereof as selective glucocorticoid receptor modulators |
| 05/05/2011 | WO2011053559A1 Aryl aminopyridine pde10 inhibitors |
| 05/05/2011 | WO2011053546A1 Methods of preparing 1-(4-((1r,2s,3r)-1,2,3,4-tetrahydroxybutyl)-1h-imidazol-2-yl)ethanone |
| 05/05/2011 | WO2011053542A1 Heterocycle amide t-type calcium channel antagonists |